Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Human Epidermal Growth Factor Receptor 2 (HER2)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT02512237
What this trial is testing

A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression

Who this might be right for
Breast NeoplasmsStomach Neoplasms
Zhejiang Medicine Co., Ltd. 9
Testing effectiveness (Phase 2)UnknownNCT00777673
What this trial is testing

Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.

Who this might be right for
Breast Cancer
University of Tennessee Cancer Institute 60
Testing effectiveness (Phase 2)Study completedNCT02491983
What this trial is testing

Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
MedSIR 486
Testing effectiveness (Phase 2)Study completedNCT04073602
What this trial is testing

RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer

Who this might be right for
Urothelial Carcinoma
RemeGen Co., Ltd. 19
Not applicableLooking for participantsNCT05677802
What this trial is testing

Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+3 more
Ohio State University Comprehensive Cancer Center 40
Testing effectiveness (Phase 2)Study completedNCT04352777
What this trial is testing

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerHormone Receptor Positive Tumor
Duke University 18
Testing effectiveness (Phase 2)Study completedNCT03735966
What this trial is testing

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

Who this might be right for
HER2 Positive Breast Cancer
Henan Cancer Hospital 75
Testing effectiveness (Phase 2)UnknownNCT05749575
What this trial is testing

Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.

Who this might be right for
Breast Cancer
Sun Yat-sen University 28
Not applicableNot Yet RecruitingNCT06495541
What this trial is testing

The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive

Who this might be right for
Breast CancerRWSPyrotinib
Tianjin Medical University Cancer Institute and Hospital 500
Early research (Phase 1)Study completedNCT03308201
What this trial is testing

Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer

Who this might be right for
Breast Cancer
Tianjin Hemay Pharmaceutical Co., Ltd 55
Not applicableEnded earlyNCT01722890
What this trial is testing

CharactHer. ICORG 12-09, V3

Who this might be right for
HER2-positive Breast CancerTNM Stage II-IV Breast Cancer
Cancer Trials Ireland 130
Testing effectiveness (Phase 2)Study completedNCT04742959
What this trial is testing

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorCholangiocarcinomaHER2-negative Breast Cancer+8 more
TransThera Sciences (Nanjing), Inc. 203
Early research (Phase 1)Study completedNCT02027376
What this trial is testing

Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients

Who this might be right for
Advanced Breast Cancer
Spanish Breast Cancer Research Group 12
Testing effectiveness (Phase 2)Looking for participantsNCT07462650
What this trial is testing

Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer

Who this might be right for
Colorectal Cancer MetastaticAdenocarcinoma of Colon
Beijing Biotech 48
Testing effectiveness (Phase 2)UnknownNCT05495724
What this trial is testing

Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Who this might be right for
Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Tianjin Medical University Second Hospital 176
Testing effectiveness (Phase 2)Ended earlyNCT02115048
What this trial is testing

Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

Who this might be right for
Breast Neoplasms
Translational Research in Oncology 44
Early research (Phase 1)Active Not RecruitingNCT02453620
What this trial is testing

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast Adenocarcinoma+2 more
National Cancer Institute (NCI) 57
Testing effectiveness (Phase 2)Ended earlyNCT01151449
What this trial is testing

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerHER2-negative Breast CancerMale Breast Cancer+7 more
National Cancer Institute (NCI) 6
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07459738
What this trial is testing

A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
Shanghai Henlius Biotech 60
Early research (Phase 1)Active Not RecruitingNCT04052555
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

Who this might be right for
Bilateral Breast CarcinomaHER2-Negative Breast CarcinomaLocalized Breast Carcinoma+2 more
National Cancer Institute (NCI) 42
Next Page